Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Allergyintellect Inc. is currently active in the Biotechnology & Pharmaceuticals technology area, with 1 pending office action on file. This activity represents the company's current efforts to protect its biological or pharmaceutical innovations. Navigating the complex requirements of the Biotechnology & Pharmaceuticals sector is a key part of the company's intellectual property strategy as it moves through the prosecution phase. Securing patent rights in this field is a key component of the company's commercial strategy.
The portfolio's pending matters are reviewed by 1 distinct examiner and are located within 1 distinct art unit. This concentration indicates that the technical scope of the applications is specialized enough to be handled by a single administrative group. For the applicant, this means that the prosecution strategy can be tailored to the specific standards of 1 distinct art unit. This focused approach can lead to a more predictable examination experience for the 1 distinct examiner assigned.
LANDAU, SHARMILA GOLLAMUDI is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. As the only examiner with a pending matter, LANDAU, SHARMILA GOLLAMUDI holds a central role in determining the outcome of the company's current patent applications. Practitioners should monitor the specific examination tendencies of this official to effectively address the 1 busiest examiner pending office action. This centralized review structure allows for direct communication with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDAU, SHARMILA GOLLAMUDI | 1 | 11.1% | +4.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17867512 | VITAMIN D COMPOUNDS AND METHODS OF USING THE SAME | LANDAU, SHARMILA GOLLAMUDI | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17867512 | VITAMIN D COMPOUNDS AND METHODS OF USING THE SAME | LANDAU, SHARMILA GOLLAMUDI | 1653 | §103DPOther | Final Rejection | — | Pending | Jul 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial